Menu
Sign In Search Podcasts Charts People & Topics Add Podcast API Pricing
Podcast Image

DeviceTalks Podcast Network

S1 Ep 1 - Zimmer Biomet's Rachel Ellingson on driving growth through portfolio shifts and M&A

03 Jan 2024

Description

In the inaugural episode of Ortho Innovation Talks: Zimmer Biomet, Rachel Ellingson, SVP and Chief Strategy Officer at Zimmer Biomet, shares insights into the company's growth strategy, emphasizing that growth can be achieved not only through addition - like innovation and acquisition - but also through subtraction, such as exiting lower growth, non-core businesses. In the episode, Ellingson discusses the decision to spin off Zimmer Biomet's spine and dental businesses and the significant undertaking required to create a new public company, which required integrating and then disintegrating business segments, building corporate infrastructure, and establishing a dedicated leadership team for the new entity - a major initiative involving over 500 people and a dedicated separation management office. Lastly, Ellingson discusses what's next in Zimmer Biomet's growth strategy, citing a balance between internal innovation and M&A and noting that the company plans to launch over 40 new products in the next 36 months, focusing on markets with at least 4% growth. Thank you to our season one sponsors, AcuityMD and Millstone Medical for supporting this podcast. To learn more about our episode sponsor, AcuityMD, please visit http://acuitymd.com. Tune in and subscribe to DeviceTalks on all major podcast channels and follow youtube.com/@DeviceTalks to ensure you never miss an episode. WATCH and LISTEN below, thank you for supporting Ortho Innovation Talks!

Audio
Featured in this Episode

No persons identified in this episode.

Transcription

This episode hasn't been transcribed yet

Help us prioritize this episode for transcription by upvoting it.

0 upvotes
🗳️ Sign in to Upvote

Popular episodes get transcribed faster

Comments

There are no comments yet.

Please log in to write the first comment.